$4.67
Insights on Inotiv Inc
Revenue is down for the last 3 quarters, 157.46M → 135.50M (in $), with an average decrease of 7.2% per quarter
Netprofit is down for the last 3 quarters, 1.84M → -15.38M (in $), with an average decrease of 342.2% per quarter
In the last 1 year, Iqvia Holdings Inc. has given 25.6% return, outperforming this stock by 34.9%
In the last 3 years, Thermo Fisher Scientific, Inc. has given 3.7% return, outperforming this stock by 81.6%
1.93%
Downside
Day's Volatility :11.92%
Upside
10.19%
65.52%
Downside
52 Weeks Volatility :85.9%
Upside
59.11%
Period | Inotiv Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 38.58% | 1.7% | 0.0% |
6 Months | 141.97% | 11.3% | 0.0% |
1 Year | -9.32% | 5.4% | 1.3% |
3 Years | -78.27% | 13.9% | -22.1% |
Market Capitalization | 125.1M |
Book Value | $9.86 |
Earnings Per Share (EPS) | -1.29 |
Wall Street Target Price | 15.5 |
Profit Margin | -5.67% |
Operating Margin TTM | -6.1% |
Return On Assets TTM | 0.4% |
Return On Equity TTM | -12.66% |
Revenue TTM | 585.2M |
Revenue Per Share TTM | 22.79 |
Quarterly Revenue Growth YOY | 10.4% |
Gross Profit TTM | 157.2M |
EBITDA | 60.9M |
Diluted Eps TTM | -1.29 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.15 |
EPS Estimate Next Year | -1.06 |
EPS Estimate Current Quarter | -0.85 |
EPS Estimate Next Quarter | -0.29 |
What analysts predicted
Upside of 231.91%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 26.3M | ↑ 8.68% |
Net Income | -194.0K | ↓ 121.95% |
Net Profit Margin | -0.74% | ↓ 4.39% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 43.6M | ↑ 65.55% |
Net Income | -790.0K | ↑ 307.22% |
Net Profit Margin | -1.81% | ↓ 1.07% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 60.5M | ↑ 38.64% |
Net Income | -4.7M | ↑ 493.04% |
Net Profit Margin | -7.75% | ↓ 5.94% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 89.6M | ↑ 48.18% |
Net Income | 10.9M | ↓ 332.55% |
Net Profit Margin | 12.16% | ↑ 19.91% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 547.7M | ↑ 511.19% |
Net Income | -337.3M | ↓ 3195.57% |
Net Profit Margin | -61.58% | ↓ 73.74% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 572.4M | ↑ 4.52% |
Net Income | -105.1M | ↓ 68.83% |
Net Profit Margin | -18.37% | ↑ 43.21% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 150.5M | ↓ 12.86% |
Net Income | -244.2M | ↑ 6766.03% |
Net Profit Margin | -162.27% | ↓ 160.21% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 150.5M | ↑ 0.0% |
Net Income | -243.6M | ↓ 0.22% |
Net Profit Margin | -161.92% | ↑ 0.35% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 151.5M | ↑ 0.66% |
Net Income | -9.6M | ↓ 96.05% |
Net Profit Margin | -6.36% | ↑ 155.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 157.5M | ↑ 3.96% |
Net Income | 1.8M | ↓ 119.11% |
Net Profit Margin | 1.17% | ↑ 7.53% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 140.7M | ↓ 10.62% |
Net Income | -9.7M | ↓ 625.16% |
Net Profit Margin | -6.87% | ↓ 8.04% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 135.5M | ↓ 3.72% |
Net Income | -15.4M | ↑ 59.25% |
Net Profit Margin | -11.36% | ↓ 4.49% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 31.3M | ↑ 53.15% |
Total Liabilities | 20.4M | ↑ 70.58% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 42.0M | ↑ 34.26% |
Total Liabilities | 31.3M | ↑ 53.4% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 61.6M | ↑ 46.72% |
Total Liabilities | 54.0M | ↑ 72.68% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 321.9M | ↑ 422.55% |
Total Liabilities | 216.7M | ↑ 301.37% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 962.9M | ↑ 199.17% |
Total Liabilities | 603.1M | ↑ 178.29% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 856.5M | ↓ 11.05% |
Total Liabilities | 588.0M | ↓ 2.5% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 962.9M | ↓ 17.54% |
Total Liabilities | 603.1M | ↑ 8.84% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 962.9M | ↑ 0.0% |
Total Liabilities | 603.1M | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 868.7M | ↓ 9.79% |
Total Liabilities | 596.0M | ↓ 1.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 854.8M | ↓ 1.59% |
Total Liabilities | 579.5M | ↓ 2.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 856.5M | ↑ 0.2% |
Total Liabilities | 588.0M | ↑ 1.47% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 835.5M | ↓ 2.45% |
Total Liabilities | 581.3M | ↓ 1.14% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.5M | ↑ 182.12% |
Investing Cash Flow | -8.1M | ↑ 2281.71% |
Financing Cash Flow | 4.9M | ↓ 680.21% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8M | ↓ 49.04% |
Investing Cash Flow | -8.1M | ↑ 0.93% |
Financing Cash Flow | 6.2M | ↑ 25.96% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.3M | ↓ 27.41% |
Investing Cash Flow | -10.1M | ↑ 24.32% |
Financing Cash Flow | 9.6M | ↑ 55.37% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.7M | ↑ 733.02% |
Investing Cash Flow | -54.1M | ↑ 433.61% |
Financing Cash Flow | 198.8M | ↑ 1962.36% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.2M | ↓ 148.55% |
Investing Cash Flow | -333.7M | ↑ 517.32% |
Financing Cash Flow | 203.2M | ↑ 2.17% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 171.0K | ↓ 101.82% |
Investing Cash Flow | -15.6M | ↑ 7.51% |
Financing Cash Flow | 14.0M | ↓ 1121.84% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 171.0K | ↑ 0.0% |
Investing Cash Flow | -15.6M | ↑ 0.0% |
Financing Cash Flow | 14.0M | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 12.8M | ↑ 7406.43% |
Investing Cash Flow | -8.4M | ↓ 46.1% |
Financing Cash Flow | -1.2M | ↓ 108.29% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.7M | ↓ 71.22% |
Investing Cash Flow | -4.5M | ↓ 46.56% |
Financing Cash Flow | -1.0M | ↓ 10.17% |
Sell
Neutral
Buy
Inotiv Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Inotiv Inc | -57.7% | 141.97% | -9.32% | -78.27% | -72.48% |
Idexx Laboratories, Inc. | -6.69% | 19.77% | 2.28% | -11.49% | 117.09% |
Agilent Technologies Inc. | -5.54% | 32.97% | 5.46% | 0.11% | 79.21% |
Thermo Fisher Scientific, Inc. | 0.67% | 33.29% | 5.29% | 16.87% | 114.21% |
Danaher Corp. | 1.05% | 29.98% | 7.94% | -2.98% | 92.05% |
Iqvia Holdings Inc. | -3.23% | 32.9% | 25.63% | 3.18% | 75.33% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Inotiv Inc | NA | NA | NA | -1.15 | -0.13 | 0.0 | NA | 9.86 |
Idexx Laboratories, Inc. | 49.04 | 49.04 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 33.3 | 33.3 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 37.17 | 37.17 | 2.81 | 21.53 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 46.53 | 46.53 | 3.13 | 7.15 | 0.08 | 0.04 | 0.0 | 72.16 |
Iqvia Holdings Inc. | 32.69 | 32.69 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Inotiv Inc | Buy | $125.1M | -72.48% | NA | -5.67% |
Idexx Laboratories, Inc. | Buy | $41.0B | 117.09% | 49.04 | 23.08% |
Agilent Technologies Inc. | Buy | $40.8B | 79.21% | 33.3 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $219.3B | 114.21% | 37.17 | 13.99% |
Danaher Corp. | Buy | $187.5B | 92.05% | 46.53 | 18.55% |
Iqvia Holdings Inc. | Buy | $43.4B | 75.33% | 32.69 | 9.06% |
Vanguard Group Inc
Balyasny Asset Management LLC
Millennium Management LLC
BlackRock Inc
Geode Capital Management, LLC
Kpp Advisory Services LLC
Inotiv Inc’s price-to-earnings ratio stands at None
Read More*we are a cro and lab instrumentation provider* basi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. we provide world-class research to the global pharmaceutical industry. our services include preclinical toxicology, early in vivo pk, bioanalysis and a full range of pharmaceutical analysis services. basi also manufactures innovative scientific instruments including the culex® automated in vivo sampling system which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. we are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on time.
Organization | Inotiv Inc |
Employees | 1955 |
CEO | Mr. Robert W. Leasure Jr. |
Industry | Healthcare |
Acorda Therapeutics, Inc.
$4.67
-3.71%
Sight Sciences Inc
$4.67
-3.71%
Sangamo Therapeutics, Inc.
$4.67
-3.71%
Corbus Pharmaceuticals Holdings, Inc.
$4.67
-3.71%
Redhill Biopharma Ltd-sp Adr
$4.67
-3.71%
Fusion Pharmaceuticals Inc
$4.67
-3.71%
Geron Corporation
$4.67
-3.71%
Iradimed Corp
$4.67
-3.71%
Dbv Technologies S.a.
$4.67
-3.71%